Navigation Links
Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin,Emerging Growth Opportunities Conference

DURHAM, N.C.--(BUSINESS WIRE)--Jul 3, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Christy L. Shaffer, Ph.D., President and CEO, will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Wednesday, July 11, 2007 at 11:00 am ET in New York City.

The webcast of the presentation will be available on Inspire's web site at www.inspirepharm.com. An archived version of the webcast presentation will also be available through this link for a limited time following the conference.

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.

Contact

Investor Contact:
Inspire Pharmaceuticals, Inc.
Jenny Kobin
VP, Investor Relations and Corporate Communications
919-941-9777, ext. 219
or
Media Contact:
BMC Communications
Dan Budwick, 212-477-9007 ext. 14


'"/>




Page: 1

Related medicine technology :

1. Inspire Announces Presentations at Two European Scientific Conferences
2. Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis
3. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... Inc., a biotechnology company focused on the development of novel ... and Head of Virology Kristin Bedard has been invited to ... Beyond meeting sponsored by Life Science Washington.  This Symposium ... PDT at the Agora Conference Center in Seattle, ... joined by other leaders in infectious disease research and the ...
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
(Date:6/8/2017)... ANGELES , June 8, 2017   Responding to ... drug oversight and the death of singer Chris Cornell ... on Human Rights International offers a free online ... better educate consumers and families about psychotropic drug risks. ... Ledger , who died from an accidental overdose, has called ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Canadian Zeolite ... that a two year study conducted by the University of Saskatchewan in partnership ... in remediating potash brine-impacted groundwater. As a part of the study, batch adsorption ...
(Date:6/28/2017)... ... 2017 , ... Doner Financial, a Cincinnati area firm that ... and financial planning services, is announcing the commencement of a local charity event ... financial crisis. , Matthew 25: Ministries (M25M) is an international organization dedicated to ...
(Date:6/28/2017)... , ... June 28, 2017 , ... ... firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up with ... lodgings for families with children receiving treatment in nearby hospitals. , Ronald McDonald ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... according to survey data released today by the American Society for Dermatologic ... indicates the percentage of consumers considering a cosmetic medical procedure has doubled ...
(Date:6/27/2017)... ... June 27, 2017 , ... Harbour , a ... assets on the Ethereum blockchain, has released their technical specifications . , 2017 ... has been little systematic approach for determining which offerings will garner the greatest ROI. ...
Breaking Medicine News(10 mins):